Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.64 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.49 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.49 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.49 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.45 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.45 |
| ▸ | DPP7 | Q9UHL4 | 8/20 | 0.43 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.43 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.43 |
| ▸ | DPP4 | P27487 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | PLG | P00747 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22163010 | 1.00 | GSR (0.64) | GSRGNAI3GNAO1GNAI1CPB2 | |
| SCHEMBL361480 | 1.00 | GSR (0.64) | GSRGNAI3GNAO1GNAI1CPB2 | |
| SCHEMBL24722227 | 1.00 | GSR (0.64) | GSRGNAI3GNAO1GNAI1CPB2 | |
| SCHEMBL361149 | 1.00 | GSR (0.64) | GSRGNAI3GNAO1GNAI1CPB2 | |
| SCHEMBL5498760 | 0.98 | GSR (0.67) | GSRGNAI3GNAO1GNAI1CPB2 | |
| SCHEMBL363001 | 0.98 | GSR (0.67) | GSRGNAI3GNAO1GNAI1CPB2 | |
| SCHEMBL358119 | 0.98 | GSR (0.67) | GSRGNAI3GNAO1GNAI1CPB2 | |
| SCHEMBL29483946 | 0.98 | GSR (0.67) | GSRGNAI3GNAO1GNAI1CPB2 | |
| Hydrochloric Acid SCHEMBL14831515 | 0.95 | GSR (0.64) | GSRGNAI3GNAO1GNAI1CPB2 | |
| Hydrochloric Acid SCHEMBL8497748 | 0.95 | GSR (0.64) | GSRGNAI3GNAO1GNAI1CPB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120277145-A1 | Compounds | WADMAN SJOERD NICOLAAS (US) | 2012-11-01 | — | — | US | claimed |
| US-9192569-B2 | Formulations for infusion of type B lantibiotics | NOVACTA BIOSYSTEMS LIMITED (GB) | 2015-11-24 | — | — | US | disclosed |
| US-9006392-B2 | Actagardine derivatives, and pharmaceutical use thereof | NOVACTA BIOSYSTEMS LIMITED (GB) | 2015-04-14 | — | — | US | disclosed |
| EP-2387580-B1 | DEOXYACTAGARDINE DERIVATIVES | NOVACTA BIOSYSTEMS LTD (GB) | 2014-08-13 | — | — | EP | disclosed |
| US-8741945-B2 | Compounds | NOVACTA BIOSYSTEMS LIMITED (GB) | 2014-06-03 | — | — | US | disclosed |
| WO-2014016613-A2 | THE USE OF TYPE-B LANTIBIOTIC-BASED COMPOUNDS HAVING ANTIMICROBIAL ACTIVITY | NOVACTA BIOSYSTEMS LIMITED (GB/GB) (GB) | 2014-01-30 | — | — | WO | disclosed |
| EP-2627320-A1 | FORMULATION COMPRISING A TYPE B LANTIBIOTIC | Novacta Biosystems Limited (GB) | 2013-08-21 | — | — | EP | disclosed |
| US-20130171252-A1 | Formulation Comprising a Type B Lantibiotic | NOVACTA BIOSYSTEMS LIMITED (GB) | 2013-07-04 | — | — | US | disclosed |
| EP-2603204-A2 | FORMULATIONS FOR INFUSION OF TYPE B LANTIBIOTICS | Novacta Biosystems Limited (GB) | 2013-06-19 | — | — | EP | disclosed |
| US-20130137630-A1 | FORMULATIONS FOR INFUSION OF TYPE B LANTIBIOTICS | NOVACTA BIOSYSTEMS LIMITED (GB) | 2013-05-30 | — | — | US | disclosed |
| US-20120302728-A1 | Actagardine Derivatives, and Pharmaceutical Use Thereof | NOVACTA BIOSYSTEMS LIMITED (GB) | 2012-11-29 | — | — | US | disclosed |
| US-20120277145-A1 | Compounds | WADMAN SJOERD NICOLAAS (US) | 2012-11-01 | — | — | US | disclosed |
| US-8283371-B2 | Compounds | NOVACTA BIOSYSTEMS LIMITED (GB) | 2012-10-09 | — | — | US | disclosed |
| US-8183278-B2 | — | — | 2012-05-22 | — | — | US | disclosed |
| WO-2012020219-A2 | FORMULATIONS FOR INFUSION OF TYPE B LANTIBIOTICS | NOVACTA BIOSYSTEMS LIMITED (GB) | 2012-02-16 | — | — | WO | disclosed |
| WO-2012007711-A1 | FORMULATION COMPRISING A TYPE B LANTIBIOTIC | NOVACTA BIOSYSTEMS LIMITED (GB) | 2012-01-19 | — | — | WO | disclosed |
| EP-2387580-A1 | DEOXYACTAGARDINE DERIVATIVES | Novacta Biosystems Limited (GB) | 2011-11-23 | — | — | EP | disclosed |
| WO-2011095769-A1 | ACTAGARDINE DERIVATIVES, AND PHARMACEUTICAL USE THEREOF | NOVACTA BIOSYSTEMS LIMITED (GB) | 2011-08-11 | — | — | WO | disclosed |
| WO-2010082018-A1 | DEOXYACTAGARDINE DERIVATIVES | NOVACTA BIOSYSTEMS LIMITED (GB) | 2010-07-22 | — | — | WO | disclosed |
| US-20100179207-A1 | COMPOUNDS | NOVACTA BIOSYSTEMS LIMITED (GB) | 2010-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179207-A1 | COMPOUNDS | VIP, DCTD, PYGB | GSR 1291/4885GNAI3 1972/4885GNAO1 1265/4885 |
| US-20130137630-A1 | FORMULATIONS FOR INFUSION OF TYPE B LANTIBIOTICS | SLC5A2, SLC5A11, SPTSSB | GSR 4554/4885GNAI3 1429/4885GNAO1 2203/4885 |
| US-20120302728-A1 | Actagardine Derivatives, and Pharmaceutical Use Thereof | GALR2, GALR1, GALR3 | GSR 2812/4885GNAI3 1127/4885GNAO1 406/4885 |
| US-20120277145-A1 | Compounds | VIP, DCTD, SI | GSR 1253/4885GNAI3 1975/4885GNAO1 1206/4885 |
| US-20130171252-A1 | Formulation Comprising a Type B Lantibiotic | CCKBR, GIPR, SI | GSR 3108/4885GNAI3 3031/4885GNAO1 1624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.